2023
DOI: 10.2337/figshare.23556180.v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira versus Basal-Bolus in Patients with Poorly Controlled Type 2 Diabetes and Very High HbA1c > 9-15%: DUAL HIGH trial

Abstract: <p><u>Introduction</u>: In participants with type 2 diabetes (T2D) and HbA1c >9.0-10.0%, guidelines recommend treatment with basal-bolus insulin. </p> <p><u>Methods</u>: Randomized trial comparing the efficacy and safety of IDegLira and basal-bolus among participants with high HbA1c <u>></u>9.0-15.0%, previously treated with 2-3 oral agents and/or basal insulin, allocated (1:1) to basal-bolus (n=73) or IDegLira (n=72). Primary endpoint was non-inferio… Show more

Help me understand this report
View published versions

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles